ISEE   $39.95  0.35% Market Closed

IVERIC bio Inc
Last Events:

2023-07-18 Trend pattern changed from расходящийся клин с наклоном вверх to восходящий клин.

2023-07-18 Signal in Stochastic changed from bearish to bullish weakening. The stochastic indicator is in overbought territory and it falls. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-07-18 Signal in MACD changed from bearish reversal to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: exit from the overbought zone.

2023-07-18 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.

2023-05-20 Signal in RSI changed from bullish recovery to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-05-19 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-05-18 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-05-17 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.


Current temperature: 0.93
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 31.93
Target: 38.88
High with 50% probability: 47.66
Analyst Recommendations:
Number of estimates 8
Target Price Mean 38.88
Mean unverified/preliminary 38.88 / 38.88
Target Price Low / High 31.00 / 40.00
Median / STD DEV 40.00 / 3.18
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - Buy ActivelyBuy
rsi Sell Sell ActivelyBuy
macd ActivelyBuy - -
stoch - - -
ma20 Sell - -
ma50 ActivelyBuy - -
ma100 Buy ActivelyBuy -
Candlestick PatternJuly 10, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US46583P1021
ceo Mr. Glenn P. Sblendorio M.B.A.
Website https://ivericbio.com
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.